Insulin Resistance as the Root of Modern Disease

The Pandemic Nobody Is Screening For

When Gerald Reaven delivered his landmark Banting Lecture in 1988 — coining the term Syndrome X to describe the clustering of insulin resistance, hyperinsulinaemia, dyslipidaemia, and hypertension — he was describing a pathological state that the medical mainstream was not yet equipped to measure, let alone prevent [1]. More than three decades later, the evidence base he seeded has expanded into one of the most robust bodies of research in metabolic medicine. And yet, in routine clinical practice across Europe, we remain largely blind to the condition he described.

Stefan and colleagues, writing in The Lancet Diabetes & Endocrinology in 2021, estimated that insulin resistance affects between 15 and 40 percent of the general adult population in high-income countries, with substantially higher rates among individuals with overweight, sedentary lifestyles, or a family history of type 2 diabetes [2]. In my practice, I see figures that support the upper end of that estimate — and I see them every week, in patients who have been told, repeatedly, that their blood tests are "normal."

This article traces the biology of insulin resistance from molecular signal to systemic disease. It explains why the condition is silent for so long, which tests unmask it, what diseases it seeds, and what interventions — grounded in mechanistic and clinical evidence — can meaningfully reverse it. It is written as a clinical reference, but also as a call to reorient our diagnostic imagination toward earlier, more precise, and ultimately more effective care.

Insulin Physiology: The Glucose-Insulin Axis in Health

Insulin is a 51-amino-acid peptide hormone synthesised and secreted by the beta cells of the pancreatic islets of Langerhans. Its release is tightly coupled to postprandial glucose elevation, but also modulated by amino acids, incretin hormones (GLP-1, GIP), the autonomic nervous system, and free fatty acid concentrations. Under physiological conditions, insulin concentration rises within minutes of a meal, peaks at approximately 30–60 minutes, and returns to fasting levels within two to three hours — a precisely orchestrated kinetic profile that governs the safe transit of nutrients from the blood into peripheral tissues [3].

Insulin Receptor Signalling: A Cascade of Precision

Insulin exerts its effects by binding to the insulin receptor (IR), a heterotetrameric transmembrane tyrosine kinase expressed on virtually every nucleated cell, with highest density on skeletal muscle, adipose tissue, and hepatocytes. Receptor binding initiates autophosphorylation of specific tyrosine residues within the intracellular beta subunit, activating a downstream signalling cascade with two primary branches [3]:

• The PI3K-Akt pathway — the metabolic arm. Insulin receptor substrate proteins (IRS-1, IRS-2) recruit phosphoinositide 3-kinase (PI3K), generating phosphatidylinositol-3,4,5-trisphosphate (PIP3), which activates protein kinase B (Akt/PKB). Akt phosphorylation drives translocation of the GLUT4 glucose transporter to the plasma membrane, inhibits glycogen synthase kinase-3 (GSK-3) to promote glycogen synthesis, and suppresses hepatic gluconeogenesis via phosphorylation of FOXO transcription factors.
• The MAPK-ERK pathway — the mitogenic arm. This branch regulates cell proliferation, gene expression, and vascular smooth muscle cell growth. It remains largely intact even when the metabolic arm is impaired — a distinction with important oncological and cardiovascular implications, as discussed below.

GLUT4: The Gatekeeper of Glucose Disposal

Of the fourteen GLUT isoforms, GLUT4 is the principal insulin-regulated transporter. In the resting, fasting state, GLUT4 resides in intracellular vesicles, sequestered away from the cell surface. Insulin-stimulated Akt activation triggers AS160 (TBC1D4) phosphorylation, releasing a brake on GLUT4 vesicle trafficking and enabling their fusion with the plasma membrane. This process increases glucose uptake into skeletal muscle by as much as 20-fold above baseline — making skeletal muscle, which accounts for roughly 80 percent of insulin-stimulated glucose disposal, the dominant sink for postprandial glucose [3].

When this process is impaired, glucose accumulates in the bloodstream. But long before hyperglycaemia develops, the body has a compensatory mechanism ready: it simply produces more insulin.

How Insulin Resistance Develops: From Ectopic Fat to Feed-Forward Loops

Insulin resistance is not a single molecular defect but a systems-level failure with multiple converging inputs. The sequence below reflects the most mechanistically characterised progression, though in clinical reality these processes occur simultaneously and reinforce one another.

Ectopic Fat Deposition and Lipotoxicity

The primary driver of peripheral insulin resistance is the accumulation of lipid intermediates — diacylglycerols (DAGs) and ceramides — within non-adipose tissues, particularly skeletal muscle and liver. When subcutaneous adipose tissue reaches its storage capacity (a threshold that is genetically variable and far lower in some individuals than commonly assumed), excess free fatty acids spill into the circulation and are taken up by muscle and hepatic cells [4].

Within muscle fibres, DAGs activate protein kinase C (PKC) isoforms, particularly PKCθ, which phosphorylate IRS-1 at serine residues rather than the tyrosine residues needed for productive downstream signalling. This serine phosphorylation acts as a molecular "off switch," decoupling insulin receptor activation from PI3K-Akt signalling and blocking GLUT4 translocation [4]. The cell becomes insulin resistant — capable of detecting insulin's presence but unable to execute its metabolic instruction.

Ceramides: The Lipotoxic Messenger

Ceramides, bioactive sphingolipids generated from saturated fatty acids via de novo synthesis, are particularly potent inhibitors of insulin signalling. They activate protein phosphatase 2A (PP2A) and atypical PKCζ/λ, both of which directly dephosphorylate and inactivate Akt — the central node of insulin's metabolic cascade [4]. Ceramide accumulation in skeletal muscle and liver correlates strongly with the degree of insulin resistance across human studies, and ceramide-lowering interventions reliably improve insulin sensitivity in animal models.

Mitochondrial Dysfunction: Energy Failure at the Cellular Level

Insulin-resistant skeletal muscle consistently demonstrates reduced mitochondrial oxidative capacity, decreased electron transport chain complex I and III activity, and impaired fatty acid beta-oxidation. Whether mitochondrial dysfunction is a cause or consequence of insulin resistance remains debated; the current evidence suggests a bidirectional relationship. Lipid overload overwhelms mitochondrial oxidative capacity, generating reactive oxygen species (ROS) and incomplete fatty acid oxidation products (acylcarnitines) that themselves impair insulin signalling. The result is a vicious cycle: more lipid, less oxidation, more lipotoxic intermediates, deeper insulin resistance [4].

Inflammation: The Immune System's Role

Adipose tissue in insulin-resistant individuals undergoes a phenotypic shift: resident anti-inflammatory M2 macrophages are progressively replaced by pro-inflammatory M1 macrophages, recruited in response to adipocyte stress, hypoxia, and free fatty acid-mediated toll-like receptor 4 (TLR4) activation. These M1 macrophages secrete tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β), all of which promote serine phosphorylation of IRS-1, perpetuating insulin signal impairment at the systemic level [4].

Crucially, this low-grade chronic inflammation is not clinically detectable by standard inflammatory markers such as CRP until the process is well advanced. It is metabolic inflammation — subclinical, pervasive, and profoundly consequential.

The Decade of Silence: Compensatory Hyperinsulinaemia

Here lies the central irony of insulin resistance: the body's most powerful defence against it — compensatory hyperinsulinaemia — is also what conceals it for so long.

As peripheral tissues become progressively less responsive to insulin, the pancreatic beta cells respond by secreting more. First-phase insulin secretion (the rapid, pre-formed release occurring within one to three minutes of glucose exposure) becomes exaggerated; second-phase secretion (the sustained synthesis-dependent release) is prolonged. The result is chronically elevated fasting insulin and disproportionately high postprandial insulin spikes — all in the service of maintaining glucose within the normal reference range [5].

Crofts and colleagues, in their 2015 review of hyperinsulinaemia, identified this compensatory phase as a distinct and clinically important pathological entity in its own right — not merely a biomarker of insulin resistance but an active contributor to disease progression through its own receptor-mediated effects on the vasculature, kidneys, sympathetic nervous system, and cell proliferation pathways [5].

DeFronzo, Matthews, and Hosker's original 1985 derivation and subsequent 1992 clinical validation of the HOMA (Homeostasis Model Assessment) model provided a mathematical framework for quantifying this compensatory state using fasting glucose and fasting insulin alone [6]. HOMA-IR = (fasting glucose [mmol/L] × fasting insulin [mIU/L]) / 22.5. Values above 1.5 are associated with meaningful insulin resistance in population studies; values above 2.5 correlate with the metabolic syndrome and substantially elevated cardiometabolic risk. Yet HOMA-IR is absent from the routine preventive panels of the vast majority of European primary care and internal medicine practices.

In my clinical experience, this is the single most common scenario I encounter. Patients present with fatigue, weight gain despite reasonable diet and exercise, brain fog, disrupted sleep, or hormonal irregularities. Their standard panels are unremarkable. When I add fasting insulin and calculate HOMA-IR, the picture changes completely — and with it, the entire clinical conversation.

From Silent Signal to Systemic Disease: The Disease Connections

Type 2 Diabetes: The Final Act of Beta-Cell Exhaustion

Type 2 diabetes is not the onset of insulin resistance — it is its end-stage consequence. The transition from compensatory hyperinsulinaemia to overt hyperglycaemia occurs when beta-cell secretory reserve declines below the threshold required to overcome peripheral resistance. This decline is progressive, driven by glucolipotoxicity-induced beta-cell apoptosis, endoplasmic reticulum stress, and mitochondrial ROS. By the time fasting glucose exceeds 7.0 mmol/L or HbA1c reaches 48 mmol/mol (6.5%), beta-cell mass and function have typically declined by 50 percent or more — a loss that is largely irreversible [1].

The clinical and public health implication is stark: diagnosing type 2 diabetes is, in most cases, diagnosing a condition that has been present, undetected, for a decade.

Cardiovascular Disease: Insulin Resistance at the Arterial Wall

The cardiovascular consequences of insulin resistance extend far beyond its role in promoting type 2 diabetes. Ginsberg's landmark 2006 review in the Journal of Clinical Investigation delineated the direct atherogenic mechanisms: hyperinsulinaemia drives hepatic VLDL overproduction, generating the characteristic dyslipidaemia of insulin resistance — elevated triglycerides, reduced HDL, and a shift toward small, dense LDL particles with greater arterial penetrance and oxidative susceptibility [7]. Insulin resistance in vascular endothelial cells selectively impairs the PI3K-Akt-eNOS branch of insulin signalling (which produces vasodilatory nitric oxide) while preserving the MAPK-ET-1 branch (which promotes vasoconstriction and smooth muscle cell proliferation), creating an endothelial dysfunction phenotype that predates atherosclerotic plaque formation by years [7].

Hyperinsulinaemia also activates the sympathetic nervous system, promotes renal sodium retention, and up-regulates angiotensin II signalling — all contributing to the hypertension that Reaven originally identified as a component of Syndrome X [1].

NAFLD/MASLD: Insulin Resistance in the Liver

Non-alcoholic fatty liver disease — now reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD) to reflect its metabolic origin — is the hepatic manifestation of insulin resistance. In the insulin-resistant liver, insulin fails to suppress FOXO1-driven gluconeogenesis (explaining fasting hyperglycaemia) but retains its lipogenic activity via SREBP-1c (explaining increased hepatic de novo lipogenesis). This selective insulin resistance results in simultaneous hepatic glucose overproduction and triglyceride accumulation — a metabolically paradoxical state that is elegantly explained by the divergent signalling pathways described above [4].

MASLD affects an estimated 25 percent of the global adult population and is now the leading cause of chronic liver disease in Europe. In the majority of cases, it is entirely preventable through early identification and reversal of insulin resistance.

PCOS: Insulin Resistance at the Hypothalamic-Pituitary-Ovarian Axis

Polycystic ovary syndrome (PCOS) affects 8–13 percent of women of reproductive age and carries a lifetime risk of metabolic disease that is substantially underappreciated in gynaecological practice. Insulin resistance is present in 65–80 percent of women with PCOS, regardless of BMI [4]. Hyperinsulinaemia directly stimulates ovarian theca cell androgen production, suppresses hepatic sex hormone-binding globulin (SHBG) synthesis (increasing free androgen bioavailability), and disrupts LH pulsatility — collectively producing the anovulation, hyperandrogenism, and follicular arrest that characterise the syndrome. Addressing insulin resistance, not merely suppressing androgens with oral contraceptives, is the mechanistically rational treatment approach.

Alzheimer's Disease: Type 3 Diabetes and Cerebral Insulin Resistance

The hypothesis that Alzheimer's disease represents a form of insulin resistance localised to the brain — colloquially termed "type 3 diabetes" — was advanced by Suzanne de la Monte and colleagues and given its most influential clinical articulation by Suzanne Craft in a 2009 review in Archives of Neurology [8]. Insulin signalling in the brain plays critical roles in neuronal survival, synaptic plasticity, amyloid-beta clearance, and tau phosphorylation. Cerebral insulin resistance — measurable by impaired insulin-stimulated glucose uptake on FDG-PET years before cognitive symptoms — promotes amyloid-beta aggregation, tau hyperphosphorylation, neuroinflammation, and mitochondrial dysfunction in neurons [8].

Epidemiological evidence is consistent with this mechanistic model: insulin resistance and hyperinsulinaemia in midlife are associated with a 65 percent increased risk of Alzheimer's disease in longitudinal cohorts [8]. This is not a statistical association without mechanism — it is a signal that the brain's metabolic environment begins to deteriorate long before plaques accumulate or cognition declines.

Cancer: Insulin as a Growth Signal

Chronically elevated insulin functions as a potent mitogen through its activation of the IGF-1 receptor and the MAPK-ERK proliferative pathway. Epidemiological evidence consistently links insulin resistance, hyperinsulinaemia, and hyperglycaemia to increased risk of breast, colorectal, endometrial, and pancreatic cancers [2]. The mechanistic pathways include: direct insulin receptor-mediated activation of cell proliferation; up-regulation of IGF-1 bioavailability (via reduced SHBG and IGF-binding proteins); increased oestrogen production from aromatase up-regulation in adipose tissue; and the provision of preferential glucose availability to metabolically active tumour cells (the Warburg effect). Cancer prevention is rarely framed in metabolic terms — but the evidence suggests it should be.

The Diagnostic Gap: Why Standard Tests Miss It

The HbA1c was designed to monitor glycaemic control in established diabetes, not to detect early insulin resistance. Its 12-week averaging window obscures postprandial glucose excursions; it is affected by red blood cell turnover, haemoglobin variants, and iron status; and, most critically, it does not rise meaningfully until compensatory hyperinsulinaemia has been sustained for years and begins to fail [5].

Fasting glucose is even less sensitive. By the time fasting glucose reaches 5.6 mmol/L — the lower boundary of impaired fasting glucose — the beta cell has already been compensating for an estimated seven to ten years. The individual is not at the beginning of metabolic dysfunction; they are approaching its end.

I have adopted a policy at Longyx of measuring fasting insulin and calculating HOMA-IR as a standard component of every metabolic assessment. I do not accept that a value of 10 mIU/L and a value of 4 mIU/L are equivalent because both fall within the laboratory reference interval. The reference interval was derived from a population that is itself largely insulin resistant. We are normalising dysfunction.

Interpreting results against optimal ranges — derived from metabolically healthy, lean, physically active individuals — rather than population-derived reference ranges is not a fringe position. It is the logical consequence of understanding that the average Western adult is not a suitable biological standard for health.

Continuous Glucose Monitoring: Reading the Postprandial Story

The postprandial period — the two to three hours following a meal — is metabolically the most revealing window in the glucose-insulin axis. Insulin resistance is fundamentally a postprandial phenomenon; fasting glucose is the last variable to be affected. CGM, by providing continuous interstitial glucose readings every one to five minutes, transforms this window from invisible to legible.

Several patterns are clinically significant even in individuals with "normal" fasting glucose and HbA1c. A postprandial glucose peak exceeding 7.8 mmol/L (140 mg/dL) is associated with increased oxidative stress, endothelial dysfunction, and postprandial inflammation regardless of fasting values. A prolonged return to baseline (glucose remaining elevated two to three hours post-meal) reflects slow glucose disposal and correlates with HOMA-IR. High glucose variability (standard deviation above 1.0 mmol/L) is an independent predictor of cardiovascular risk in non-diabetic individuals [5].

For patients who have never seen their own metabolic response to food, a fortnight of CGM data is frequently the single most transformative clinical intervention I offer — not because it treats anything, but because it makes the invisible visible. Numbers on a graph change behaviour in ways that statistical risk scores rarely do.

What Moves Insulin Sensitivity: Evidence-Based Interventions

Time-Restricted Eating

Time-restricted eating (TRE) — limiting food intake to an 8–10 hour window aligned with circadian light-dark cycles — has accumulated a robust evidence base for improving insulin sensitivity independent of caloric restriction. The mechanisms include reduced nocturnal insulin secretion, improved hepatic fatty acid oxidation, enhanced autophagy and mitochondrial biogenesis, and restoration of circadian clock gene expression in metabolic tissues. A 2019 randomised controlled trial in men with metabolic syndrome demonstrated that five weeks of TRE (eating window 6:00–15:00) produced significant reductions in fasting insulin, blood pressure, and oxidative stress without caloric restriction [4].

Resistance Training

Skeletal muscle is the primary site of insulin-stimulated glucose disposal. Resistance training increases GLUT4 protein content, enhances post-exercise insulin sensitivity for 24–72 hours via AMPK-mediated mechanisms, reduces intramyocellular lipid accumulation, and promotes mitochondrial biogenesis. Meta-analyses consistently demonstrate that resistance training reduces HOMA-IR by 10–30 percent in insulin-resistant adults, with dose-response relationships favouring two to four sessions per week at moderate-to-high intensity [4]. The effect is additive to aerobic exercise and partly independent of weight loss.

High-Intensity Interval Training (HIIT)

HIIT produces disproportionate metabolic adaptations relative to its time investment through AMPK activation, rapid glycogen depletion (creating a post-exercise glucose sink), and potent stimulation of mitochondrial biogenesis via PGC-1α. Comparative trials consistently show HIIT to be at least as effective as matched-volume moderate-intensity continuous training for improving insulin sensitivity, with superior effects on VO₂max and mitochondrial content — both independently associated with longevity [4].

Targeted Nutritional Interventions

Several micronutrients and phytochemicals have demonstrated mechanistically coherent and clinically relevant effects on insulin sensitivity:

• Berberine (1000–1500 mg/day in divided doses): An isoquinoline alkaloid that activates AMPK — the cellular energy sensor — in skeletal muscle and liver, with effects on fasting glucose and insulin sensitivity comparable to metformin in direct comparative trials. Its mechanisms include inhibition of complex I of the mitochondrial respiratory chain (triggering AMPK), reduction of hepatic lipogenesis, and modulation of the gut microbiome toward short-chain fatty acid-producing species [4].
• Magnesium (300–400 mg elemental/day): Cofactor for over 300 enzymatic reactions including pyruvate kinase, hexokinase, and the insulin receptor tyrosine kinase. Magnesium deficiency impairs insulin receptor signalling and is prevalent in insulin-resistant individuals. Supplementation in magnesium-deficient insulin-resistant adults consistently reduces fasting insulin and HOMA-IR.
• Myo-inositol and D-chiro-inositol: These phosphatidylinositol precursors act as second messengers in insulin signalling. Myo-inositol (2–4 g/day) is particularly well-evidenced in PCOS, reducing fasting insulin, improving ovarian function, and restoring menstrual cyclicity with a safety profile superior to metformin in comparative trials [4].
• Omega-3 fatty acids (EPA/DHA): Reduce hepatic lipogenesis, lower triglycerides, attenuate adipose tissue inflammation, and improve insulin sensitivity in skeletal muscle by modifying cell membrane phospholipid composition and reducing ceramide synthesis from saturated fatty acids.

Dietary Quality Beyond Macronutrients

The evidence does not support a single macronutrient composition as universally optimal for insulin sensitivity. What is robustly supported is the reduction of ultra-processed foods (high in refined carbohydrates, fructose, seed oils, and food additives that disrupt the gut microbiome), the prioritisation of dietary fibre (which attenuates postprandial glucose via multiple mechanisms including delayed gastric emptying, increased GLP-1 secretion, and gut microbiome-mediated short-chain fatty acid production), and the importance of protein adequacy for preserving lean muscle mass — the primary glucose disposal organ [2].

The Longyx Approach: Measuring What Matters

At Longyx, our metabolic assessment begins where most standard panels end. We routinely measure fasting insulin alongside fasting glucose, calculate HOMA-IR, and where appropriate, extend to a full oral glucose tolerance test with concurrent insulin measurement. We interpret every value against optimal reference intervals — the ranges associated with metabolic health and longevity, not merely the absence of formal disease.

We offer continuous glucose monitoring as an elective add-on to metabolic assessments, not because CGM is inherently superior to blood testing, but because experiential data — seeing your own glucose curve respond to your own food, stress, sleep, and exercise — carries a motivational and educational weight that laboratory numbers alone rarely achieve.

We do not wait for HOMA-IR to reach 2.5 before we act. A HOMA-IR of 1.5 in a 38-year-old, set against a clinical history of fatigue, weight gain, disrupted sleep, and a family history of type 2 diabetes, is not a reassuring finding. It is an intervention opportunity — and intervention opportunities, by definition, close over time.

Our approach is not to alarm patients — elevated fasting insulin and a HOMA-IR of 1.8 are not a diagnosis of diabetes. They are an invitation to act, years before the window closes. That is precisely the territory in which precision longevity medicine operates, and precisely where it has the most to offer.

Conclusion

Insulin resistance is not a pre-diabetic curiosity. It is the central metabolic dysfunction of our era — the upstream driver of type 2 diabetes, cardiovascular disease, MASLD, PCOS, Alzheimer's disease, and several common cancers. It operates silently for a decade or more, concealed behind normal glucose values and normal HbA1c, while compensatory hyperinsulinaemia works to hold the system together — at enormous and mounting biological cost.

The tools to detect it exist. Fasting insulin, HOMA-IR, and continuous glucose monitoring are not experimental interventions; they are established, inexpensive, and actionable. The interventions to reverse it are evidence-based, available without prescription, and effective long before pharmacological thresholds are reached. What is needed is not new science, but a new diagnostic standard — one that prioritises optimal metabolic function over the mere absence of formal disease.

Reaven's 1988 insight has never been more relevant. The question is whether we will build clinical systems capable of acting on it — before the curtain falls.